Limits...
Overcoming tumor immune evasion with an unique arbovirus.

Lyday B, Chen T, Kesari S, Minev B - J Transl Med (2015)

Bottom Line: Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms.Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock.While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells.

View Article: PubMed Central - PubMed

Affiliation: PrimeVax, LLC, Garden Grove, USA. bruce.lyday@primevax.com.

ABSTRACT
Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms. Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock. While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells. The premise of using multiple mechanisms of action in synergy with a decline in the ability of the tumor cells to employ resistance methods suggests the potential of this combination approach in cancer immunotherapy.

No MeSH data available.


Related in: MedlinePlus

Mechanisms in protective TH1 responses and exacerbating TH2 responses.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4307212&req=5

Fig4: Mechanisms in protective TH1 responses and exacerbating TH2 responses.

Mentions: Secondary dengue infections induce a TH2 type response mainly due to preexisting titers of semi-neutralizing IgG antibody [38,45,52]. Activated macrophages with up-regulated Fc-receptors engulf these complexes but become infected with the non-neutralized virus [36]. These infected macrophages secrete TNFα and TH2 type cytokines which suppress CTL and NK responses and lead to greatly increased vascular permeability, resulting in hemorrhage and shock (Figure 4) [52,65].Figure 4


Overcoming tumor immune evasion with an unique arbovirus.

Lyday B, Chen T, Kesari S, Minev B - J Transl Med (2015)

Mechanisms in protective TH1 responses and exacerbating TH2 responses.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4307212&req=5

Fig4: Mechanisms in protective TH1 responses and exacerbating TH2 responses.
Mentions: Secondary dengue infections induce a TH2 type response mainly due to preexisting titers of semi-neutralizing IgG antibody [38,45,52]. Activated macrophages with up-regulated Fc-receptors engulf these complexes but become infected with the non-neutralized virus [36]. These infected macrophages secrete TNFα and TH2 type cytokines which suppress CTL and NK responses and lead to greatly increased vascular permeability, resulting in hemorrhage and shock (Figure 4) [52,65].Figure 4

Bottom Line: Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms.Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock.While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells.

View Article: PubMed Central - PubMed

Affiliation: PrimeVax, LLC, Garden Grove, USA. bruce.lyday@primevax.com.

ABSTRACT
Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms. Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock. While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells. The premise of using multiple mechanisms of action in synergy with a decline in the ability of the tumor cells to employ resistance methods suggests the potential of this combination approach in cancer immunotherapy.

No MeSH data available.


Related in: MedlinePlus